- $1.06bn
- $1.26bn
- $272.30m
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates
Brief: Harrow Inc Q1 Gross Margin 61%
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy
Brief: Harrow To Initiate Phase 3 Clinical Trial Seeking To Expand Triesence® Label To Include Ocular Inflammation And Pain Following Cataract Surgery Indication
U.S. STOCKS ON THE MOVE-Cheniere Energy, silver miners, Target Corp
Drugmaker Harrow slumps after forecasting annual revenue below estimates
Harrow Q4 revenue slightly beats estimates
Brief: Harrow Inc Q4 Gross Margin 79%
Eye care drugmaker Harrow swings to Q3 profit
Brief: Imprimisrx Announces Leadership Changes
U.S. RESEARCH ROUNDUP-Carvana, Marvell Technology, Wayfair
Brief: Harrow Inc - On Sept 26, Enters Credit Agreement With Fifth Third Bank - SEC Filing
Brief: Harrow to Acquire Melt Pharmaceuticals
Brief: Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
Brief: Harrow Appoints Andrew R. Boll As President - SEC Filing